A new study by UW researchers will test gene editing therapy to treat blindness. The collaborative project involves a team of ophthalmology researchers and biomedical engineers.
gene therapy
ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Teaming Up for Gene Therapy
*This article originally appeared in the McPherson Eye Research Institute Summer 2021 InSights Newsletter Millions of Americans currently battle inherited visual disorders, armed with very few therapeutic options. Recent advances in genome editing, which many believe …
Can precision medicine treat childhood blindness?
Using stem cells, gene therapy to correct errors in retinal cells A research team at the University of Wisconsin School of Medicine and Public Health has shown that two novel approaches to treating an inherited …
It’s a Go – The Clinical Trials Unit Embarks on the First Human Gene Therapy Trial in DOVS History
The University of Wisconsin-Madison Department of Ophthalmology and Visual Sciences (DOVS) has formally been announced as a partner site for Nightstar Therapeutics’ STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia. This is the first …